FutureChemLtd Valuation

Is A220100 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A220100 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A220100's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A220100's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A220100?

Key metric: As A220100 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A220100. This is calculated by dividing A220100's market cap by their current revenue.
What is A220100's PS Ratio?
PS Ratio	23.3x
Sales	₩14.92b
Market Cap	₩347.36b

A220100 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	21.9x
Enterprise Value/EBITDA	-127.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A220100's PS Ratio compare to its peers?

The above table shows the PS ratio for A220100 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	17.7x
A445680 Curiox Biosystems	55.1x	n/a	₩303.9b
A268600 Cellivery Therapeutics	10.9x	n/a	₩244.9b
A038290 Macrogen	1.2x	16.9%	₩164.2b
A278650 HLB bioStepLtd	3.6x	n/a	₩179.8b
A220100 FutureChemLtd	23.3x	n/a	₩347.4b

Price-To-Sales vs Peers: A220100 is expensive based on its Price-To-Sales Ratio (23.3x) compared to the peer average (20x).

Price to Sales Ratio vs Industry

How does A220100's PS Ratio compare vs other companies in the KR Life Sciences Industry?

2 Companies	Price / Sales	Estimated Growth	Market Cap
A245620 Eone Diagnomics Genome Center	0.8x	n/a	US$41.47m
A215380 WOOJUNG BIO	0.6x	n/a	US$19.78m

No more companies available in this PS range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A220100 is expensive based on its Price-To-Sales Ratio (23.3x) compared to the KR Life Sciences industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is A220100's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A220100 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	23.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A220100's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

JW Pharmaceutical

₩591.4b

Manufactures and sells medicines and medical supplies in Japan and internationally.

A001060

₩23,650.00

-2.9%

-20.6%

Hugel

₩2.8t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩272,000.00

-3.5%

79.4%

J2KBIO

₩54.3b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,540.00

3.6%

n/a